Simple jQuery Dropdowns

Browsing by Author Helen Barraclough

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)
1-Jan-2014First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trialJames Chih Hsin Yang; Jin Hyoung Kang; Tony Mok; Myung Ju Ahn; Vichien Srimuninnimit; Chia Chi Lin; Dong Wan Kim; Chun Ming Tsai; Helen Barraclough; Sedat Altug; Mauro Orlando; Keunchil Park; National Taiwan University Hospital; The Catholic University of Korea; Chinese University of Hong Kong; SungKyunKwan University, School of Medicine; Mahidol University; Seoul National University Hospital; Veterans General Hospital-Taipei; Eli Lilly and Company
1-May-2011Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervixAlfonso Dueñas-González; Juan J. Zarbá; Firuza Patel; Juan C. Alcedo; Semir Beslija; Luis Casanova; Pittayapoom Pattaranutaporn; Shahid Hameed; Julie M. Blair; Helen Barraclough; Universidad Nacional Autonoma de Mexico; Medical Center; Eli Lilly Interamerica; Postgraduate Institute of Medical Education and Research; National Institute of Oncology; University of Sarajevo; Instituto Nacional de Enfermedades Neoplsicas; Mahidol University; Shaukat Khanum Memorial Cancer Hospital and Research Centre; Eli Lilly Australia Pty Ltd.